Table 6.

Estimation of elongase and desaturase activity in the nonprogression and the progression group

Fatty acids ratioEnzymatic activityNonprogression (n = 34)Progression (n = 14)Pa
20:3n6/18:3n6Elovl5 elongaseMean ± SD4.33 ± 12.062.49 ± 6.99
Median (IQR)0.00 (0.00–0.00)0.00 (0.00–0.00)0.89
22:4n6/20:4n6Elovl2 elongaseMean ± SD0.14 ± 0.030.16 ± 0.04
Median (IQR)0.14 (0.12–0.16)0.15 (0.13–0.16)0.34
20:4n3/18:4n3Elovl5 elongaseMean ± SD0.12 ± 0.600.20 ± 0.73
Median (IQR)0.00 (0.00–0.00)0.00 (0.00–0.00)0.88
22:5n3/20:5n3Elovl2 elongaseMean ± SD3.95 ± 3.541.79 ± 2.87
Median (IQR)4.02 (0.00–4.98)0.00 (0.00–3.29)0.01
18:1n9/18:0Δ9-desaturaseMean ± SD2.14 ± 1.422.40 ± 2.24
Median (IQR)1.73 (1.12–2.66)1.42 (1.10–2.16)0.70
18:3n6/18:2n6Δ6-desaturaseMean ± SD0.00 ± 0.000.00 ± 0.00
Median (IQR)0.00 (0.00–0.00)0.00 (0.00–0.00)1.00
18:4n3/18:3n3Δ6-desaturaseMean ± SD0.15 ± 0.200.07 ± 0.12
Median (IQR)0.07 (0.00–0.24)0.00 (0.00–0.18)0.15
20:4n6/20:3n6Δ5-desaturaseMean ± SD4.78 ± 0.914.86 ± 1.42
Median (IQR)4.76 (4.00–5.52)4.52 (3.63–6.49)0.83
20:5n3/20:4n3Δ5-desaturaseMean ± SD0.29 ± 1.270.028 ± 0.11
Median (IQR)0.00 (0.00–0.00)0.00 (0.00–0.00)0.80

NOTE: The progression group had a lower conversion rate of docosapentaenoic acid (22:5n3) from EPA (20:5n3) than the nonprogression group, as measured by the Elovl2 elongase activity. Prostate cancer progression is defined as biopsy-detected Gleason 7 at the first repeat biopsy session.

Bold font indicates significance at P < 0.05.

  • aP values were obtained by using the Fligner-Policello test.